Much better to panic early than late. The VX1-VX2 spread helps you define when market participants are starting to panic. The backwardation / reversal is a sign that market participants are starting to panic. In this sense we can use it as a risk mitigation tool, including the distributions of returns for the stock market and the volatility when futures are in...
VW is working with partners to improve battery system performance and costs down to the cell level. It plans to call a new battery cell in 2023 to be used in up to 80% of VW Group's electric vehicles by 2030. VW expects to reduce battery costs by up to 50% in the entry-level segments and up to 30% in the mid-market segments. loud volume. VW, together with...
In the last quarter the company has beaten all estimates, both in terms of sales and earnings per share. Azure cloud revenue merely matched analysts’ expectations and the company said it would acquire Activision Blizzard for $68.7 one of the best video game manufacturers. Although a growing dividend and the ongoing stock repurchase program are certainly...
A FED taper is bullish for bonds. Since 2002, there's nearly a 90% correlation between the price movement of stocks and bonds. On 30's the key level of support is at 1.825%. A long bond position right now is a long VOL position. You are betting on weaker global growth and inflation expectations along with the potential for a major risk-off event that would trigger...
On a technical level we have a first support at 1.1260, target that we expect by the end of the month. However it should be noted that this situation is the corresponding effective function of the world that does NOT have enough dollars, (to pay the debts denominated in the USA), as crazy as it may seem. A dollar shortage occurs when a country spends more US...
Unilever on Thursday reported higher-than-expected third quarter underlying sales growth, as it hiked prices in response to cost inflation. The consumer goods and food maker said underlying sales rose 2.5% for the three months to September 30, beating the 2.2% of analysts' forecasts. Growth was boosted by good demand in the US, India, China and Turkey, while a...
What will the ECB do after March 2022? Currently, ECB buys European bonds and government bonds through two programs: with Pepp (the pandemic program) it buys each month for 70 billion euros, while with App (the residue of the "old" quantitative easing) buys another 20 billion. In March, this being the case, only the 20 billion App program will remain alive: the...
The “Buy the Dip” correlation has really changed: the intermarket scenario, in which this umpteenth rebound and recovery takes place, has perhaps reached its peak. Indeed, commodity prices have risen by 43% in the last 12 months. In the same period, yields rose by 90 bps on the ten-year US bond, despite a monetary policy that is still hyper-expansive. We believe...
The pickup up in oil quotations this year is lifting profits nicely and we believe that this trend can continue throughout the next year. Strong demand in the chemicals division and a lower cost structure are also helping performance. The high dividend yield likely indicates concerns about oil demand and the push for electric vehicles over the very long term. That...
The rise in commodities has not yet accelerated oil prices, and we know that if crude oil does not rise to at least $ 90, we will hardly be able to have "lasting" inflation. So the goal of the Central Banks, if they want to return to having an inflation capable of bringing down the huge stocks of debt, must bet everything on the price of crude oil. And from this...
China is slowing down and by a lot, Evergrande doesn't help, the United States can't wait to do excursions and the Eurozone freezes in the land of the "poor". The increase in yields is not about the great economic growth we are paying for. US economy is clearly in a better position than the European one; GDP growth rate is higher. The Fed holds over 70% of all...
We can bet that there will be a recession before 2024. The reverse repo agreements of the Fed surges to all-time highs in 2021, with those financial firms parking more than $ 1 trillion in funds at the Fed since August. Isn't that related to Evergrande's failure? The first signs began right towards May/June. Evergrande has not paid interest on maturing dollar...
Fed officials say tapering ‘may soon be warranted’ and interest rates rise penciled in for 2022. Powell says announcement on tapering bond purchases could come in November. The formal announcement could come at the Fed’s Nov. 2-3 meeting, barring a major setback for the economy or another coronavirus outbreak, Powell indicated. In updated projections, the Fed also...
This has to be considered as a trading idea. If Evergrande should fail, HSBC is one of the main holders of the securities, between January and July, HSBC added 40% more in Evergrande bond shares, but total portfolio exposure is down to 1.22%. Are we really sure that there will be no contagion on financial groups?
The stock has had a strong graphical expansion, and is currently in a very well set up bullish channel. We have identified two entry points that could be interesting if a financial event or recession occurs. The P/E is on very tight levels and the dividend at current prices is not attractive. We await a correction for a possible entry.
the company has very attractive corporate multiples with a P/E around 12, debt under control and a good dividend yield. The problem is that the market does not like it, but an investment at these prices, especially if it falls below $ 50, could prove to be very interesting in the medium or long term. 75% of microchips are manufactured in Asia, and that is THE...
Interesting graphical retracement for the Amgen stock which sees a considerable decline from the highs of the year. Where does the caution stem from? First, management highlighted that new patient prescriptions remain below pre-COVID-19 levels, and second, variants are suggesting demand may be muted for now. The stock has a solid capital appreciation potential and...
The Swiss-based drugmaker missed consensus expectations on both earnings and sales in the first quarter, the results were hurt by a historically weak cough and cold season. Novartis’ cornerstone innovative medicines division turned in with sales +4%. Stock is currently pegged to underperform the broader market and our 18-month projections reflect below-average...